Lendormin (Brotizolam)

Brotizolam binds to the benzodiazepine site on the GABA‑A receptor, enhancing the inhibitory effect of the neurotransmitter GABA. This increased chloride influx hyperpolarizes neurons, producing sedative, hypnotic, anxiolytic, and muscle‑relaxant actions that facilitate sleep.

The appropriate dose of Lendormin is determined by the prescribing clinician based on the patient’s condition, age, and response to therapy. Dosage adjustments are made individually, and patients should follow the prescriber’s instructions exactly.

Safety of Brotizolam in pregnancy or lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Lendormin (Brotizolam) is a short‑acting benzodiazepine, offering rapid onset of sleep with a relatively brief duration, which can reduce next‑day residual effects compared with longer‑acting agents. However, it shares the class‑related risks of dependence and tolerance, which must be weighed against alternatives such as non‑benzodiazepine hypnotics.

Lendormin tablets should be stored at ambient temperature, below 25 °C, in their original packaging. Protect them from moisture, direct sunlight, and excessive heat to maintain product stability.

Lendormin is taken orally as a tablet, usually shortly before bedtime. Patients should swallow the tablet whole with a glass of water and avoid taking it with or after a heavy meal that could delay absorption.

Serious risks include respiratory depression, especially when combined with other CNS depressants, development of physical dependence, withdrawal symptoms upon abrupt discontinuation, and rare but severe allergic reactions. Patients should be monitored closely for these events.

Lendormin is contraindicated in individuals with known hypersensitivity to Brotizolam or other benzodiazepines, patients with severe respiratory insufficiency, acute narrow‑angle glaucoma, and those who are currently abusing alcohol or other sedatives. It should also be used with caution in the elderly and in patients with hepatic or renal impairment.